Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Basilea Pharmaceutica
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03230318 | https://clinicaltrials.gov/study/NCT04045613
Assets
Linked programs
- derazantinib: Watchlist Signal (2/5)
- Derazantinib 300 mg once daily monotherapy: Watchlist Signal (2/5)